Deoxycholic acid
Deoxycholic Acid, Kybella (deoxycholic acid) is a small molecule pharmaceutical. Deoxycholic acid was first approved as Kybella on 2015-04-29. It is known to target fMet-Leu-Phe receptor, bile acid receptor, and G-protein coupled bile acid receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Deoxycholic acid, Kybella
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kybella | New Drug Application | 2024-10-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Deoxycholic Acid, Kybella, Abbvie | |||
| 8101593 | 2030-03-02 | DP | |
| 8367649 | 2030-03-02 | DP | |
| 8653058 | 2030-03-02 | DP | |
| 10500214 | 2030-03-02 | DP | |
| 8242294 | 2028-05-16 | DP | |
| 8461140 | 2028-02-21 | DP | |
| 8546367 | 2028-02-21 | DP | U-1690 |
| 8883770 | 2028-02-21 | DP | |
| 9522155 | 2028-02-21 | DP | U-1940 |
| 9636349 | 2028-02-21 | U-1940 | |
| 9949986 | 2028-02-21 | U-1940 | |
| 7622130 | 2027-12-10 | U-1690 | |
| 7754230 | 2027-12-10 | U-1690 | |
| 8298556 | 2025-08-03 | U-1690 | |
| 8846066 | 2025-02-08 | U-1690 | |
HCPCS
Code | Description |
|---|---|
| J0591 | Injection, deoxycholic acid, 1 mg |
Clinical
Clinical Trials
222 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biliary liver cirrhosis | D008105 | — | K74.3 | 3 | 5 | 9 | 3 | 5 | 23 |
| Fibrosis | D005355 | — | — | 3 | 2 | 4 | 1 | 5 | 14 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 6 | 1 | 3 | 3 | 13 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | 1 | 2 | 2 | 2 | 5 | 11 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 3 | 1 | 4 | 1 | 3 | 11 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | 5 | 2 | 8 |
| Gallstones | D042882 | EFO_0004210 | — | — | — | 2 | 4 | 1 | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 2 | 2 | 1 | 7 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 3 | 4 | 2 | — | 7 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | 3 | 3 | 7 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | 1 | 4 | — | — | 19 |
| Cholestasis | D002779 | — | K83.1 | — | 6 | 6 | — | 4 | 13 |
| Intrahepatic cholestasis | D002780 | — | — | — | 4 | 4 | — | 1 | 7 |
| Colorectal neoplasms | D015179 | — | — | 1 | 4 | 2 | — | — | 5 |
| Cerebrotendinous xanthomatosis | D019294 | — | — | 1 | 1 | 1 | — | 2 | 5 |
| Xanthomatosis | D014973 | — | — | 1 | 1 | 1 | — | 2 | 5 |
| Infections | D007239 | EFO_0000544 | — | — | — | 2 | — | 3 | 5 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | 1 | 3 | — | — | 3 |
| Pregnancy complications | D011248 | — | — | — | 1 | 2 | — | 1 | 3 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | 1 | 1 | — | 1 | 3 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 2 | — | — | 2 | 4 |
| Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 2 | 2 | — | — | 1 | 4 |
| Lipoma | D008067 | — | D17.9 | 2 | 1 | — | — | 1 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | — | — | 1 | 3 |
| Meningitis | D008581 | EFO_0000584 | G03 | 2 | 1 | — | — | 1 | 3 |
| Gastrointestinal diseases | D005767 | — | — | 1 | 3 | — | — | — | 3 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | 1 | 3 | — | — | — | 3 |
| Mucormycosis | D009091 | EFO_0007380 | B46.5 | — | 1 | — | — | 1 | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 2 | — | — | — | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 2 | — | — | — | 2 |
Show 42 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurofibromatosis 1 | D009456 | — | Q85.01 | 4 | — | — | — | — | 4 |
| Neurofibroma | D009455 | EFO_0000622 | — | 3 | — | — | — | — | 3 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 1 | — | — | — | 1 | 2 |
| Neurofibromatoses | D017253 | — | Q85.00 | 2 | — | — | — | — | 2 |
| Clostridium infections | D003015 | EFO_1000874 | A05.2 | 1 | — | — | — | 1 | 2 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
| Echolocation | D004455 | — | — | 1 | — | — | — | — | 1 |
| Hyperlipoproteinemia type iv | D006953 | Orphanet_413 | E78.1 | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | — | — | — | 3 | 3 |
| Alcoholic fatty liver | D005235 | — | K70.0 | — | — | — | — | 2 | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | — | 1 | 1 |
| Peroxisomal disorders | D018901 | Orphanet_44 | E71.5 | — | — | — | — | 1 | 1 |
| Zellweger syndrome | D015211 | Orphanet_912 | E71.510 | — | — | — | — | 1 | 1 |
| Infantile refsum disease | D052919 | Orphanet_772 | G60.1 | — | — | — | — | 1 | 1 |
| Adrenoleukodystrophy | D000326 | Orphanet_43 | E71.52 | — | — | — | — | 1 | 1 |
| Refsum disease | D012035 | Orphanet_773 | G60.1 | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Sarcoma | D012509 | — | — | — | — | — | — | 1 | 1 |
Show 29 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deoxycholic acid |
| INN | deoxycholic acid |
| Description | Deoxycholic acid is a bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively. It has a role as a human blood serum metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of a deoxycholate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 83-44-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL406393 |
| ChEBI ID | 28834 |
| PubChem CID | 222528 |
| DrugBank | DB03619 |
| UNII ID | 005990WHZZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FPR1
FPR1
NR1H4
NR1H4
GPBAR1
GPBAR1
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kybella – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Kybella – Kythera Biopharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Kybella – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 32,672 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,781 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use